Levodopa-carbidopa intrajejunal infusion in Parkinson's disease: untangling the role of age

被引：10

作者：

Morgante, Francesca ^{[1
,2
]}

Oppo, Valentina ^{[3
]}

Fabbri, Margherita ^{[4
,5
]}

Olivola, Enrica ^{[6
]}

Sorbera, Chiara ^{[7
]}

De Micco, Rosa ^{[8
]}

Ielo, Giovanna Chiara ^{[9
]}

Colucci, Fabiana ^{[10
]}

Bonvegna, Salvatore ^{[11
]}

Novelli, Alessio ^{[11
]}

Modugno, Nicola ^{[6
]}

Sensi, Mariachiara ^{[10
]}

Zibetti, Maurizio ^{[12
]}

Lopiano, Leonardo ^{[12
]}

Tessitore, Alessandro ^{[8
]}

Pilleri, Manuela ^{[9
]}

Cilia, Roberto ^{[11
]}

Elia, Antonio E. ^{[11
]}

Eleopra, Roberto ^{[11
]}

Ricciardi, Lucia ^{[1
,13
]}

Cossu, Giovanni ^{[3
]}

机构：

[1] St Georges Univ London, Mol & Clin Sci Res Inst, Neurosci Res Ctr, Cranmer Terrace, London SW17 0RE, England

[2] Univ Messina, Dept Expt & Clin Med, Messina, Italy

[3] AO Brotzu, Dept Neurosci, Movement Disorders & Neurophysiol Unit, Piazzale Ricchi 1, I-09134 Cagliari, Italy

[4] Univ Toulouse 3, Clin Invest Ctr CIC 1436, Parkinson Toulouse Expert Ctr, NS Pk FCRIN Network,Dept Neurosci, Toulouse, France

[5] Univ Toulouse 3, INSERM, Toulouse Univ Hosp, NeuroToul COEN Ctr, Toulouse, France

[6] IRCCS Neuromed, Neurol Unit, Pozzilli, IS, Italy

[7] IRCCS Ctr Neurolesi Bonino Pulejo, Neurorehabil Unit, Messina, Italy

[8] Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci, Naples, Italy

[9] Private Hosp, Serv Neurol, Arcugnano, Italy

[10] Azienda Osped Univ S Anna, Dept Neurosci & Rehabil, Ferrara, Italy

[11] Fdn IRCCS Ist Neurol Carlo Besta, Movement Disorder Unit, Milan, Italy

[12] Univ Torino, Dept Neurosci Rita Levi Montalcini, Turin, Italy

[13] Nuffield Dept Clin Neurosci, MRC Brain Network Dynam Unit, Oxford, England

来源：

JOURNAL OF NEUROLOGY | 2021年 / 268卷 / 05期

基金：

英国医学研究理事会;

关键词：

Parkinson’ s disease; Motor fluctuations; Dyskinesia; Levodopa– carbidopa intestinal gel (LCIG); Old age; Quality of life; DEEP BRAIN-STIMULATION; SUBTHALAMIC NUCLEUS; DISORDERS; CRITERIA; ISSUES;

D O I：

10.1007/s00415-020-10356-x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objectives Levodopa-Carbidopa Intrajejunal gel (LCIG) infusion is an effective intervention for people with advanced Parkinson's disease (PD). Although age may not be a limiting factor for LCIG implant, no data are available on late elderly PD (LE-PD) subjects. In this cross-sectional, we aimed to demonstrate if older age may impact on quality of life (QoL), motor and non-motor symptoms severity, and profile of side effects in PD treated with LCIG. Methods Out of 512 PD subjects treated with LCIG at 9 Italian PD centers, we selected 25 LE-PD defined as age >= 80 years at last follow-up who were available to attend the study visit. Twenty-five PD patients (Control-PD, defined as age < 75 years at last follow-up) matched to LE-PD by disease and LCIG duration served as control group. The following motor and non-motor variables were ascertained: quality of life (PDQ-8), time spent in ON, wearing-off Questionnaire, Unified PD Rating Scale, freezing of gait questionnaire, Parkinson's disease sleep scale-2, Non Motor Symptoms Scale (NMSS), and MOCA. Results No statistically significant differences were found between LE-PD and Control-PD on PDQ-8 and several motor and non-motor variables. LE-PD had less frequent and milder impulsive-compulsive behaviors and milder dyskinesia. At multivariable regression, worse quality of life was associated with UPDRS-III and NMSS scores but not to age at study visit and age at LICG implant. Rate of adverse effects was similar in both groups. Drop-out rate calculated in the whole PD cohort was comparable between the two groups. Conclusion Our data provide evidence that valuable LCIG infusion might be achieved in late elderly PD.

引用

页码：1728 / 1737

页数：10

共 28 条

[1] Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach [J].